Lipopolysaccharide-binding protein and future Parkinson's disease risk: a European prospective cohort.

ABSTRACT:

Introduction

Lipopolysaccharide (LPS) is the outer membrane component of Gram-negative bacteria. LPS-binding protein (LBP) is an acute-phase reactant that mediates immune responses triggered by LPS and has been used as a blood marker for LPS. LBP has recently been indicated to be associated with Parkinson's disease (PD) in small-scale retrospective case-control studies. We aimed to investigate the association between LBP blood levels with PD risk in a nested case-control study within a large European prospective cohort.

Methods

A total of 352 incident PD cases (55% males) were identified and one control per case was selected, matched by age at recruitment, sex and study center. LBP levels in plasma collected at recruitment, which was on average 7.8 years before diagnosis of

SUBMITTER: Zhao Y 

PROVIDER: S-EPMC10362572 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature